Narroway Harry G, Kovacic James L, Bourke Bernard M, Louis-Johnsun Mark, Latif Edward R, Bourke Victor C
Department of Vascular Surgery, 90112Gosford Hospital, Gosford, NSW, Australia.
Department of Urology, 90112Gosford Hospital, Gosford, NSW, Australia.
Vasc Endovascular Surg. 2022 Jun 9:15385744221108041. doi: 10.1177/15385744221108041.
The purpose of this study was to report our centre's experience using selective angioembolisation in the treatment of iatrogenic renal artery pseudoaneurysms (RAP) following minimally invasive urological procedures.
Our retrospective analysis included four consecutive patients treated with angioembolisation for iatrogenic RAP between October 2016 and October 2021. Data on demographics, minimally invasive urological intervention, clinical features, imaging findings, embolization procedure and perioperative details were collected. Rates of technical and clinical success, defined as 1. total occlusion of the extravasation site on completion digital subtraction angiography (DSA), and 2. resolution of symptoms, signs, and serum hemoglobin (Hb) derangements secondary to RAP, were analysed. Renal function, measured by serum creatinine (Cr) and estimated glomerular filtration rate (eGFR), was recorded prior to and post - angioembolisation procedure and compared.
Mean time between urological intervention and angioembolisation was 9 days (range, 2-17 days). Rates of technical and clinical success were 100% and 100% respectively. No additional angioembolisation procedures were required, and there were no peri or post-operative complications identified during mean follow-up of 662 days (range, 30-1845 days). Mean serum Cr prior to and post angioembolisation was 83 mmol/L and 79.5 mmol/L. Mean eGFR prior to and post angioembolisation was 73.8 and 77.8 mL/min/1.73 m2. In all patients, no significant difference was observed in serum Cr and eGFR prior to and post angioembolisation.
Iatrogenic renal artery pseudoaneurysms can occur following a range of minimally invasive urological procedures. This retrospective review highlights the utility of angioembolisation as a safe and effective treatment with high clinical and technical success rates. Further studies involving larger populations are required to validate its broader application.
本研究的目的是报告我们中心在微创泌尿外科手术后使用选择性血管栓塞治疗医源性肾动脉假性动脉瘤(RAP)的经验。
我们的回顾性分析纳入了2016年10月至2021年10月期间连续4例接受血管栓塞治疗医源性RAP的患者。收集了人口统计学数据、微创泌尿外科干预措施、临床特征、影像学检查结果、栓塞过程及围手术期详细信息。分析了技术成功率和临床成功率,技术成功率定义为数字减影血管造影(DSA)完成时外渗部位完全闭塞,临床成功率定义为RAP继发的症状、体征及血清血红蛋白(Hb)紊乱得到缓解。在血管栓塞术前和术后记录通过血清肌酐(Cr)和估算肾小球滤过率(eGFR)测量的肾功能,并进行比较。
泌尿外科干预与血管栓塞之间的平均时间为9天(范围2 - 17天)。技术成功率和临床成功率分别为100%和100%。无需额外的血管栓塞操作,在平均662天(范围30 - 1845天)的随访期间未发现围手术期或术后并发症。血管栓塞术前和术后的平均血清Cr分别为83 mmol/L和79.5 mmol/L。血管栓塞术前和术后的平均eGFR分别为73.8和77.8 mL/min/1.73m²。所有患者血管栓塞术前和术后的血清Cr和eGFR均无显著差异。
一系列微创泌尿外科手术后可能发生医源性肾动脉假性动脉瘤。这项回顾性研究强调了血管栓塞作为一种安全有效的治疗方法的实用性,临床和技术成功率都很高。需要进一步开展涉及更大样本量人群的研究来验证其更广泛的应用价值。